Now this is a fine way to begin a week on the stock market. Summit Therapeutics (NASDAQ: SMMT) saw its stock price rise ...

This year, Summit Therapeutics Inc. (SMMT) leads the parade of winners among large stocks (those with a market value of $10 ...

JMP Securities initiated coverage on Summit Therapeutics Inc. (NASDAQ:SMMT), noting the company’s initial focus on infectious ...

Summit Therapeutics Inc's innovative approach to combating serious infectious diseases positions it as a potential leader in ...

Fintel reports that on November 4, 2024, JMP Securities initiated coverage of Summit Therapeutics (NasdaqGM:SMMT) with a ...

Summit Therapeutics PLC ( (SMMT) ) has realeased its Q3 earnings. Here is a breakdown of the information Summit Therapeutics PLC presented to ...

Now this is a fine way to begin a week on the stock market. Summit Therapeutics (NASDAQ: SMMT) saw its stock price rise notably Monday, on the happy news that an analyst has initiated coverage ...

In terms of valuation, Summit Therapeutics Inc’s market capitalization stands at $14.71 billion. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s ...

On Thursday, Summit Therapeutics Inc (SMMT) stock saw a decline, ending the day at $18.59 which represents a decrease of $-0.06 or -0.32% from the prior close of $18.65. The stock opened at $18.75 and ...

The 6th RNAi-Based Therapeutics Summit is returning to Boston in January 2025 with fresh insights and perspectives.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Summit Therapeutics. The Motley Fool has a disclosure policy.